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Abstract More than 90% of the population is infected by Epstein-Barr virus (EBV), which has
sophisticatedly evolved to survive silently in B cells for the life of infected individuals. However,
if the virus-host balance is disturbed, latent EBV infection could be associated with several lym-
phomas. The age at primary infection varies substantially worldwide, and exposure to EBV is
likely to be due to socioeconomic factors. In Argentina, EBV infection is mostly subclinical and
90% of patients are seropositive by the age of 3 years; therefore, its epidemiological charac-
teristics resemble those of an underdeveloped or developing population. EBV-positive Hodgkin
lymphoma (HL) in young adults from developed populations has been attributed to delayed
primary EBV infection as suggested by the association with recent mononucleosis development.
EBV-associated Burkitt lymphoma and Hodgkin lymphoma in children from Argentina display fre-
quencies similar to those observed in developed countries, whereas EBV presence in pediatric
diffuse large B-cell lymphoma is slightly increased compared to those populations. However,
EBV presence is statistically associated particularly with patients < 10 years of age in all three
entities. Therefore, a relationship between low age of EBV seroconversion and B-cell lymphoma
development risk could be suggested in children from Argentina.
© 2015 Hospital Infantil de México Federico Gómez. Published by Masson Doyma México S.A. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
PALABRAS CLAVE Epidemiología de linfomas pediátricos asociados con el virus de Epstein-Barr
Virus de Epstein-Barr; en Argentina
la población se encuentra infectada con el virus de Epstein-Barr
soﬁsticadamente para sobrevivir de por vida de manera silenciosaLinfoma de Hodgkin;
Linfoma de Burkitt;
Linfoma difuso de
Resumen Más del 90% de
(VEB), que ha evolucionadocélulas B;
Linfoma pediátrico
en las células B de individuos infectados. Sin embargo, si el balance entre el virus y el huésped
se altera, la infección latente por VEB se podría asociar con linfomas severos. La edad de la
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infección  primaria  varía  sustancialmente  a  escala  global,  y  la  exposición  al  VEB  al  parecer  se
relaciona  con  factores  socioeconómicos.  En  Argentina,  la  infección  por  VEB  es  mayormente
subclínica,  y  el  90%  de  los  pacientes  son  seropositivos  a  la  edad  de  3  an˜os.  Por  lo  tanto,  las  car-
acterísticas  epidemiológicas  se  asemejan  a  aquellas  de  una  población  subdesarrollada  o  en  vías
de  desarrollo.  El  linfoma  de  Hodgkin  (LH)  positivo  para  VEB  en  adultos  jóvenes  se  ha  atribuido
a  una  infección  por  VEB  tardía  en  economías  desarrolladas,  como  lo  sugiere  la  asociación  con  el
desarrollo  de  mononucleosis.  En  Argentina,  el  linfoma  de  Burkitt  y  el  linfoma  de  Hodgkin  asoci-
ados  con  VEB  en  nin˜os  presentan  frecuencias  similares  a  las  observadas  en  países  desarrollados,
mientras  que  la  presencia  de  VEB  en  el  linfoma  difuso  de  células  B  pediátrico  se  encuentra
con un  ligero  aumento  comparado  con  estas  poblaciones.  Sin  embargo,  la  presencia  de  VEB
en  los  tres  padecimientos  se  asocia  estadísticamente,  en  particular,  con  pacientes  menores  de
10  an˜os.  Por  ello,  se  podría  sugerir  una  la  relación  entre  la  menor  edad  de  seroconversión  y  el
riesgo  de  desarrollo  de  linfoma  de  células  B  en  nin˜os  de  Argentina.
© 2015  Hospital  Infantil  de  México  Federico  Gómez.  Publicado  por  Masson  Doyma  México
S.A.  Este  es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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c. Introduction
pstein--Barr  virus  (EBV)  is  a  ubiquitous  double-stranded  DNA
irus that  belongs  to  the  Herpesviridae  family  and  Gamma-
erpesvirinae subfamily.  EBV  is  characterized  by  a  tropism
or B-lymphocytes  displaying  latent  infection  in  the  host  and
he capacity  for  transforming  B-lymphocytes.  More  than  90%
f the  population  worldwide  carries  the  virus,1 which  has
ophisticatedly evolved  to  survive  in  B  cells  for  the  life  of
nfected individuals.  The  result  is  a  ﬁnely  balanced  relation-
hip that  allows  the  virus  to  be  acquired  silently  early  in  life
nd carried  thereafter  as  a  lifelong  asymptomatic  infection
n the  B  lymphoid  system.  However,  the  virus-host  balance
an be  disturbed  in  various  ways,  and  one  of  a  range  of  virus-
ssociated diseases  may  then  ensue.2 Latent  EBV  infection  is
inked to  many  human  malignancies.  In  immunocompetent
ersons, EBV  is  associated  with  ∼20%  of  Burkitt  lymphoma
BL) in  the  developed  world,  almost  all  African  BL,  50%  of
odgkin lymphoma  (HL),  10%  gastric  carcinomas,  almost  all
ndemic nasopharyngeal  carcinoma  (NPC),  certain  fractions
f diffuse  large  B-cell  lymphoma  and  T-cell  lymphoma.  In  the
bsence of  normal  T-cell  immune  responses,  EBV-infected
-lymphocyte proliferations  can  cause  lymphoproliferative
isease (LPD),  similar  to  post-transplant  LPD.  The  persis-
ence of  EBV  genomes  in  cells  of  these  malignancies,  even
n subjects  with  otherwise  normal  immune  response,  is  con-
istent with  the  notion  that  EBV  genomes  are  important  for
alignant cell  growth.3
The  age  at  primary  infection  varies  substantially  world-
ide, and  exposure  to  EBV  is  likely  to  be  due  to
ocioeconomic factors.  Young  children  most  likely  acquire
rimary EBV  infection  due  to  close  contact  that  involves
xchange of  oral  secretions  via  shared  items  such  as  toys,
ottles, and  utensils.  Before  the  age  of  10  years,  pri-
ary infection  is  usually  asymptomatic.  In  adolescents  and
oung adults,  however,  primary  EBV  infection  frequently
resents as  infectious  mononucleosis  (IM).  Seroprevalence
f EBV  varies  widely  by  geographic  location.  Data  indicate
hat primary  EBV  infection  occurs  at  a  younger  age  among
ersons from  lower  vs.  higher  socioeconomic  backgrounds,
hich has  been  attributed  to  crowded  living  conditions.4
 delay  in  acquiring  a  primary  EBV  infection  at  an  older
w
p
m
oge  in  childhood  or  adolescence,  which  usually  occurs  in
ore developed  countries,  can  manifest  itself  as  infec-
ious mononucleosis,  occurring  in  ∼25--75%  of  EBV-infected
ersons.5 The  severity  of  primary  EBV  infection  in  adults
ncreases with  age,  and  patients  >  40  years  of  age  are  espe-
ially prone  to  serious  illness.  EBV  infections  in  children
 10  years are  often  overlooked,  either  because  they  are
ntirely asymptomatic  or  because  they  do  not  present  with
 typical  IM  syndrome.4
There  is  a  hypothesis  that  proposes  that  the  clini-
al presentation  variability  related  to  the  age  of  EBV
rimary infection  is  linked  to  the  different  magnitude
f the  viral  dose  received  by  a  child  or  a  young
dult through  salivary  contact.6 Another  possibility  is
hat IM  in  adolescents  may  reﬂect  the  global  CD8+
-cell lymphocytosis,  with  a  great  proportion  of  activated
BV-speciﬁc CD8+  T-cells.7 In  contrast,  it  was  recently
escribed in  children  from  Africa  that  asymptomatic  EBV
nfection elicits  a  virus-speciﬁc  CD8+  T-cell  response  that
an control  the  infection,  without  CD8+  T-cells  over-
xpansion.8 Moreover,  it  was  suggested  that  preexisting  NK
ell populations  in  children  may  provide  an  explanation  for
hy IM  occurs  more  frequently  in  adolescents  and  adults
han in  children.9 In  Argentina,  EBV  infection  is  mostly  sub-
linical and  90%  of  patients  are  seropositive  by  the  age  of  3
ears; therefore,  its  epidemiological  characteristics  resem-
le those  of  an  underdeveloped  or  developing  population.10
. EBV infection in relation to lymphoma
evelopment
s  previously  mentioned,  EBV  is  among  the  infectious
gents whose  clinical  manifestations  vary  according  to  age
t  primary  infection.  Moreover,  its  epidemiological  behav-
or is  similar  to  that  of  HL.  The  relatively  few  cases  of
BV-positive HL  in  younger  adults  may  be  attributed  to
elayed primary  EBV  infection  as  suggested  by  the  asso-
iation with  mononucleosis.11 In  fact,  IM  was  associated
ith an  increased  risk  of  EBV-positive  HL,  along  with  the
articularly pronounced  risk  in  younger  adults.  Further-
ore, IM-associated  lymphomas  occurred  with  a  median
f 2.9  years  after  infection  in  patients  from  a  developed
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pEpidemiology  of  Epstein-Barr  virus-associated  pediatric  lymp
population.  Although  the  idea  that  EBV  is  merely  an  eti-
ologically innocent  passenger  in  the  neoplastic  HL  cells
cannot easily  be  dismissed,  it  remains  more  likely  that  the
observed association  indeed  reﬂects  causality,12 at  least  in
cases with  recent  IM  development.  In  contrast,  no  associa-
tions between  EBV  serology  status,  elevated  antibody  titers
against EBNA-1,  EBNA-2,  VCA,  or  EA,  and  risk  of  non-Hodgkin
lymphoma (NHL)  overall  was  demonstrated  in  immunocom-
petent individuals,  with  the  possible  exception  of  chronic
lymphocytic leukemia  (CLL).  Therefore,  it  was  proposed  that
the biological  mechanism  for  the  causal  role  of  EBV  in  the
pathogenesis of  NHL  would  predominantly  involve  immune
system deregulation.13
The  temporal  risk  variation  in  HL  after  IM  suggests  that
the predilection  for  the  younger  adult  age  group  may  simply
result from  the  combination  of  age  and  time  since  IM  rather
than from  other  mechanisms  particular  to  HL  in  younger
adults.14 It  is  therefore  tempting  to  speculate  that  a sim-
ilar association  may  exist  between  primary  EBV  infection
and HL  risk  at  any  age,  e.g.,  in  childhood.12 EBV  epidemiol-
ogy in  Argentina  reﬂects  a  typical  pattern  of  a  developing
country with  primary  infection  in  early  childhood  and  the
epidemiology of  EBV-related  lymphomas  differs  from  that
observed in  developing  countries.  Therefore,  EBV  infection
in our  pediatric  patients  shows  a  complex  epidemiological
pattern, very  attractive  to  investigate.
3. EBV in pediatric Hodgkin lymphoma
In  the  United  States  and  most  European  countries,  HL  shows
an annual  incidence  of  4.5-6.0  per  million  and  its  inci-
dence increases  with  age  and  peaks  between  15  and  30
years. In  contrast,  in  developing  countries,  it  shows  a  high
incidence in  children  exceeding  7  per  million  per  annum
and 70%  of  cases  occur  in  children  <  10  years  of  age.15
EBV  presence  in  HL  varies  with  geographic  location,  age,
sex, clinical  stage,  and  histologic  type.  EBV  is  detected
in Hodgkin  Reed-Sternberg  (HRS)  cells  in  ∼40%  of  classical
HL in  the  Western  world,  mostly  in  cases  of  mixed  cel-
lularity (MC)  and  lymphocyte-depleted  subtypes,  and  less
frequently in  nodular  sclerosis  and  lymphocyte-rich  classical
subtypes. EBV  is  rarely  found  in  nodular  lymphocyte  predom-
inant HL  (NLPHL).16 Developing  countries  have  an  increased
incidence of  EBV-positive  cases,  which  may  be  attributed  to
the existence  of  underlying  immunosuppression.17 In  addi-
tion, in  developed  populations  EBV-positive  HL  also  affects
more Asians  and  Hispanics  than  whites  or  blacks  and  in  the
UK is  more  common  in  South  Asian  children  compared  with
non-South Asian  children.15
Childhood  HL  is  deﬁned  as  affecting  those  patients
≤16 years  of  age.  It  represents  ∼10%  of  all  diagnosed  HL
and typically  shows  a  signiﬁcant  prevalence  of  male  gender
and MC  subtype  (30-35%)  in  comparison  with  HL  in  ado-
lescent/young adults  or  adults.  Like  its  adult  counterpart,
∼40-50% of  HL  cases  are  associated  with  EBV  in  devel-
oped countries.18 HL  is  more  likely  to  be  EBV-associated  to
boys <  10  years  of  age  than  to  young  adults.  This  led  to
the suggestion  that  HL  consists  of  three  disease  entities:
pediatric HL  (EBV-positive,  mixed  cellularity  type),  HL  of
young adults  (EBV-negative,  nodular  sclerosis  type),  and  HL
of older  adults  (EBV-positive,  mixed  cellularity  type).15
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In  Argentina,  our  group  previously  reported  an  epidemi-
logical pattern  II  together  with  an  EBV  association  of  31%
or adult  HL,  which  rose  up  to  54%  in  pediatric  patients.19--21
n  pediatric  HL  in  Central  and  South  America,  several
roups demonstrated  an  EBV-association  that  could  be  up
o 90%.16 Therefore,  EBV  presence  in  childhood  HL  from
ur series  resembles  the  scenario  observed  in  developed
ountries. In  spite  of  this,  EBV  was  statistically  associ-
ted with  MC  subtype  and  males  (p  <  0.05,  2 test),  typical
f an  underdeveloped  or  developing  population.  In  addi-
ion, when  only  children  <  10  years  of  age  were  analyzed,
hey displayed  distinctive  characteristics.  EBV  was  statis-
ically distributed  in  74%  of  patients  <  10  years  of  age
s. 34%  observed  in  patients  11-16  years  (p  <  0.0001,  2
est).  Furthermore,  EBV+  cases  had  a median  age  of  8
ears vs.  a  median  of  12  years  observed  in  EBV-  cases
p =  0.006,  Mann-Whitney  test)  (authors’  unpublished  data).
hese paradoxical  epidemiological  characteristics  make  our
opulation a quite  interesting  group  for  analysis.  In  con-
rast, in  southeast  Brazil,  where  both  EBV  primary  infection
nd EBV-associated  pediatric  HL  reveal  the  same  pattern
s in  Argentina,  EBV+  HL  was  not  signiﬁcantly  distributed
n patients  <  10  years  of  age  or  MC  subtype.22,23 However,
hildhood HL  from  northeast  Brazil  display  87%  of  EBV+  cases
ogether with  a  prevalence  of  MC  subtype,24 as  in  underde-
eloped populations.  In  line  with  this,  Mexico  and  Peru  also
howed a  high  frequency  of  EBV-associated  HL,  70%  and  94%,
espectively.25,26
EBV-associated  tumors  display  three  classical  patterns
ith differential  expression  of  latency  proteins,  in  part
s a  consequence  of  host  immune  response  to  EBV  anti-
ens. Latency  III  expresses  EBNA1,  -2,  -3A,  -3B,  -3C,  -LP
ogether with  LMP1  and  -2  and  the  non-coding  RNAs  (EBERs,
icroRNAs, and  BARTs),  typically  associated  with  post-
ransplant lymphoproliferative  disorders.  All  other  latency
ypes involve  increasing  degrees  of  viral  gene  silencing.  In
atency I,  observed  in  BL,  only  EBNA1  and  the  non-coding
NAs are  expressed,  whereas  EBNA1,  LMP1  and  -2  and  the
on-coding RNAs  are  expressed  in  the  latency  II program,
elated to  HL.27 It  was  proposed  that  LMP1  rescue  pro-
poptotic germinal  center  B-cells  with  crippling  mutations
n the  heavy  chain  immunoglobulin  locus  from  apoptosis,28
hereas  LMP2A  may  act  as  an  indispensable  BCR-mimic  in
CR-positive and  BCR-negative  germinal  center  B-cells,29
ointing  to  its  crucial  role  in  the  rescue  of  these  cells
rom apoptosis  and  in  the  HL  transformation  process  as
ell. On  the  other  hand,  Thorley-Lawson  et  al.  suggested
 modest  signaling  role  for  LMP1  and  LMP2A  in  GC  B-cells,
ased on  the  presence  of  high  afﬁnity  antibodies  in  LMP1
nd LMP2A  positive  germinal  center  B-cells.30 In  Argentina,
e found  latency  II  pattern  in  our  HL  series,  deﬁned  by
MP1 expression  in  cytoplasm  membrane  of  HRS  cells.  Given
hat HRS  cells  derive  from  crippled,  pre-apoptotic  germi-
al center  B-cells,16 LMP1  expression  in  our  cases  could  be
esponsible for  rescuing  those  cells  from  apoptotic  stimuli.
n a  preliminary  study  of  LMP1  expression  in  tonsils  from
ediatric EBV+  patients,  we  found  that  LMP1+  cells  were
revalent outside  the  germinal  centers  (authors’  unpub-
ished data).  This  fact  could  imply  that  LMP1  presence  in
nly a  small  number  of  cases  might  prevent  apoptosis  and
ead to  ﬁrst  steps  in  malignant  transformation  towards  HRS
ells.
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The  risk  of  HL  after  IM  suggests  that  the  predilection  for
he younger  adult  age  group  may  simply  result  from  the  com-
ination of  age  and  time  since  IM.  Therefore,  given  the  fact
hat in  Argentina  primary  infection  occurs  at  early  age  and
s mostly  subclinical,  and  HL  prevail  in  patients  <  10  years
ld, a  similar  association  may  exist  between  primary  EBV
nfection and  HL  risk  in  childhood.
. EBV in pediatric Burkitt lymphoma
urkitt  lymphoma  (BL)  can  be  classiﬁed  into  three  forms,
hich differ  in  geographic  distribution  and  EBV  association:
ndemic (eBL),  sporadic  (sBL)  and  HIV-associated  BL.31 The
igh-incidence ‘‘endemic’’  form  typically  presents  as  a  jaw
r  abdominal  tumor  in  children  in  areas  of  equatorial  Africa
nd Papua  New  Guinea  where  malaria  is  holoendemic  and  is
lmost 100%  EBV+.  Elsewhere,  BL  occurs  in  ‘‘sporadic’’  form,
gain mainly  in  children,  at  intermediate  to  low  incidence
nd with  different  degrees  of  EBV  association  depending
pon the  area.  Western  countries  show  the  lowest  inci-
ence rates  and  the  weakest  virus  association,  with  only
5% to  20%  tumors  being  EBV+.  Remarkably,  a  third,  adult
orm of  the  tumor,  AIDS-BL,  proved  to  be  very  common
mong HIV-infected  individuals,  often  appearing  as  one  of
he ﬁrst  symptoms  of  AIDS;  30%  to  40%  of  these  tumors  carry
BV.32 The  hallmark  of  all  BL  tumors  is  the  translocation
etween the  MYC  gene  and  one  of  the  immunoglobulin  (Ig)
eavy or  light  chain  loci.31 BL  cells  phenotypically  resem-
le centroblasts.  Moreover,  many  BL  cells  and  also  some
L-derived cell  lines  show  evidence  of  active  somatic  hyper-
utation, a  further  hallmark  of  germinal-center  B  cells.  The
tructure of  the  chromosome  breakpoints  derived  from  the
nalysis of  MYC-Ig  translocations  strongly  indicates  that  the
ranslocations occurred  either  as  a  mistake  of  class  switch
ecombination or  somatic  hypermutation,  both  processes
hat occur  in  germinal-center  B  cells.33 There  is  some  evi-
ence that  the  original  cell  may  derive  from  a  post-GC  or
emory B  cell  re-entering  the  GC  and  may  differ  in  EBV-
ositive and  -negative  tumors;  however,  it  is  clear  that
erminal center  involvement  is  critical  for  the  pathogene-
is of  this  disease  both  in  terms  of  MYC  translocation  events
nd the  contribution  of  co-factors  such  as  EBV,  malaria  or
IV infection.31
In  Argentina,  our  group  demonstrated  an  EBV  association
ith pediatric  BL  in  37%  of  cases,  including  immunocom-
etent and  immunocompromised  patients.  All  HIV+  patients
100%) were  EBV+,  whereas  29%  of  the  immunocompetent
atients displayed  EBV  presence  in  tumor  cells.  EBV  pres-
nce in  BL  biopsies  was  analyzed  according  to  age,  and  the
irus was  statistically  distributed  in  patients  <  5  years  old
p < 0.0001,  2 test).  Furthermore,  as  also  demonstrated  for
BV-associated HL,  the  median  age  of  EBV-positive  patients
as lower  (3  years  old)  than  that  observed  for  EBV  nega-
ive ones  (8  years  old)  (p  =  0.0027,  Mann--Whitney  test).34
emarkably,  a  sporadic  EBV  association  with  BL  (29%)  in
mmunocompetent patients  was  observed  in  our  series.
n contrast,  variable  regionally  EBV  association  with  BL  was
escribed in  Brazil,  varying  from  29%  in  the  South  to  76%  in
he North,  but  higher  in  pediatric  groups  from  all  regions.35
he  scenario  for  BL  in  HIV-infected  patients  was  quite  dif-
erent from  that  described  previously  because  these  series
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howed  an  interesting  100%  EBV  association  with  pediatric
L patients  infected  with  HIV,  higher  than  the  typical  30-40%
eported for  this  entity.32
Latency  I  pattern  seen  in  most  endemic  BL  tumors  is
haracterized by  the  restricted  expression  of  a  single  latent
ntigen EBNA1  transcribed  from  Qp  viral  promoter,  differ-
nt from  the  latency  III  EBNA  transcripts,  which  are  driven
y either  of  two  promoters,  Cp  or  Wp.  However,  another
ype of  latency,  termed  Wp-restricted  latency,  character-
zed by  expression  of  EBNA1,  EBNA3A,  EBNA3B,  EBNA3C,
BNA-LP and  BHRF1in  the  absence  of  EBNA2  and  the  LMPs,
as also  demonstrated  in  a  subset  of  endemic  BL  tumors  that
arry EBV  genomes  deleted  for  the  EBNA2  gene.33 For  that
eason, we  studied  viral  latency  proﬁles  by  LMP1  immuno-
istochemistry and  RT-PCR.  Most  EBV+  cases  (80%)  displayed
he typical  latency  I  proﬁle  described  in  BL,  whereas
he remaining  20%  showed  also  LMP1  immunohistochemi-
al expression,  remarkably  those  cases  were  HIV-infected
atients. This  pattern  did  not  match  either  with  latency  I
r  Wp-restricted  pattern  described  for  Burkitt  lymphoma  or
ith latency  III  pattern  associated  with  EBV-positive  lym-
homas in  immunosuppressed  patients.  In  addition,  LMP2A
atent gene  as  well  as  BZLF1  and  BHRF1  lytic  genes  were  not
etected by  RT-PCR,  whereas  EBNA1  transcripts  driven  from
p promoters  were  demonstrated  in  the  absence  of  Wp/Cp
romoter usage.34 Only  one  group  has  previously  reported
MP1 expression  without  LMP2A  by  RT-PCR  in  2  eBL  patients
rom Africa.36 It  can  be  hypothesized  that  LMP1  expression
n BL  patients  infected  with  HIV  could  arise  from  a  germinal
enter cell  that  failed  to  turn-off  selectively  LMP1  expres-
ion to  achieve  the  full  BL  latency  I  phenotype,  promoted  by
IV presence.  Alternatively,  the  presence  of  HIV-associated
mmunosuppression allows  the  unchecked  proliferation  of
BV-infected lymphocytes  expressing  latent  antigens  differ-
nt  from  typical  latency  I.34
. EBV in pediatric diffuse large B-cell
ymphoma
orldwide,  diffuse  large  B-cell  lymphoma  (DLBCL)  rep-
esents the  most  common  subtype  of  NHL,  accounting
or 30%  to  40%  of  all  newly  diagnosed  cases.  Two  dis-
inct subtypes  have  been  identiﬁed,  termed  germinal
enter cell  and  post-germinal  center,  which  are  believed
o represent  lymphomas  arising  from  different  stages  of
ymphoid differentiation.37 The  2008  World  Health  Organi-
ation (WHO)  classiﬁcation  of  tumors  of  hematopoietic  and
ymphoid tissues  has  recognized  a  new  provisional  entity
esignated as  EBV-positive  DLBCL  of  the  elderly.  It  has
een postulated  that  EBV-positive  DLBCL  of  the  elderly
ight be  caused  by  the  senescence  of  the  immune  sys-
em as  a  part  of  the  normal  aging  process,  based  largely
n shared  features  with  immunodeﬁciency-LPDs.38 The  age
utoff  for  EBV-positive  DLBCL  was  set  as  >  50  years.  How-
ver, recent  reports  show  that  EBV-positive  DLBCL  can
ffect younger  patients,39 including  our  study.40 Further-
ore, in  some  previous  reports,  patients  <  50  years  old  were
ven excluded  from  the  studies.39 Therefore,  it  is  not  evi-
ent that  EBV-positive  DLBCL  in  young  adults  has  distinct
linical features  and  outcome  compared  to  their  elderly
ounterpart.
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Table  1  Comparison  between  EBV  positive  and  negative  pediatric  lymphomas  between  developed  countries  and  Argentina.
Pediatric Hodgkin lymphoma Pediatric  Burkitt lymphoma Pediatric diffuse large B-cell lymphoma
Developed
countries
Argentina Developed
countries
Argentina Developed
countries
Argentina
Annual incidence/million 4.5-6.0 6.94 Annual incidence/million Uncertain 2.93 Annual incidence/million Uncertain Uncertain
Peak age at presentation
EBV+
Adolescent/young
adult
8 years Peak age at presentation
EBV+
Adolescent/young
adult
3 years Peak age at presentation
EBV+
Adolescent/young
adult
6 years
Peak age at presentation
EBV-
Adolescent/young
adult
12 years Peak age at presentation
EBV-
Adolescent/young
adult
11 years Peak age at presentation
EBV-
Adolescent/young
adult
11 years
% of EBV+ ≥10 y group Uncertain  34% % of EBV+ ≥10 y group Uncertain 34% % of EBV+ ≥10 y group Uncertain 10%
% of EBV+ ≤10 y group Uncertain 74% % of EBV+ ≤10 y group Uncertain 80% % of EBV+ ≤10 y group Uncertain 60%
Overall % of EBV+
pediatric  HL
40-50% 54% % of EBV positive sBL 15-20% 29% % of EBV-positive IC
DLBCL
Uncertain  26%
Latency type Classic latency II Classic
latency II
% of EBV positive HIVaBL 30-40%  100% % of EBV positive
HIVaDLBCL
Uncertain 100%
% of EBV positive in all BL Uncertain  37% % of EBV positive in all
DLBCL
Uncertain  40%
Latency type Classic latency I 80% latency 1
20%  latency I + LMP1
Latency type Uncertain Latency III > II  with
some  lytic replication
sBL, sporadic Burkitt lymphoma; HIVaBL, HIV-associated Burkitt lymphoma; IC DLBCL, immunocompetent diffuse large B-cell lymphoma; HIVaDLBC, HIV-associated diffuse large B-cell lymphoma.
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DLBCL  is  rarely  diagnosed  in  children  <  4  years  of  age,
ut the  proportion  of  patients  with  DLBCL  increases  through-
ut childhood  toward  the  second  decade  of  life.41 The  role
f EBV  in  pediatric  DLBCL  pathogenesis  remains  uncertain;
herefore, we  assessed  EBV  association  as  well  as  viral  gene
xpression in  the  DLBCL  pediatric  population  from  our  hos-
ital. EBV  association  with  DLBCL  rose  up  to  40%,  using  20%
f EBERs+  cells  as  cut-off  value;  nevertheless,  when  exclud-
ng immunosuppressed  patients,  this  association  decreased
o 26%.42 There  are  only  few  studies  dealing  with  EBV  pres-
nce in  DLBCL.  Our  overall  percentage  was  very  similar  to
hose observed  in  previous  reports  restricted  to  African  chil-
ren, which  analyzed  series  of  NHL  that  included  a  subset  of
LBCL and  described  an  association  of  43-44%  between  EBV
nd this  lymphoma  subtype,  even  though  the  immunolog-
cal status  of  these  patients  was  not  clearly  speciﬁed.43,44
BV  presence  in  pediatric  DLBCL  patients  was  sorted  in
wo age  groups:  less  than  10  years  (≤10  years)  and  11--16
ears (>10  years).  The  number  of  EBV+  cases  was  sig-
iﬁcantly higher  among  patients  ≤  10  years  than  among
atients >  10  years (p  <  0.018,  Fisher’s  exact  test).  Moreover,
edian age  of  EBV-positive  patients  was  6  years  vs.  11  years
bserved in  the  negative  patients  (p  =  0.005,  Mann  Whitney
est). This  observation  together  with  the  high  association
n childhood  HL  as  well  as  BL  conﬁrms  that  EBV  could  be
n important  cofactor  in  B-cell  lymphomagenesis  in  younger
hildren in  Argentina.42
Previous  studies  suggested  that  EBV+  DLBCL  in  elderly
atients generally  showed  a  viral  latency  type  II  or  III
attern,45,46 whereas  viral  latency  pattern  was  not  pre-
iously described  in  pediatric  and  young  adults  patients.
n our  pediatric  DLBCL  series,  latency  pattern  III  was  the
ost frequently  observed  together  with  lytic  gene  expres-
ion, followed  by  latency  II  pattern.42 BZLF1  lytic  gene
xpression could  mirror  a  percentage  of  cells  undergoing
ytic phase,  as  previously  observed  for  BL.47 A  mixture  of
atency II  or  III  and  a  lytic  EBV  gene  was  also  observed
n our  adult  lymphoma  series  from  Argentina,  in  both
atients younger  and  older  than  50  years.40 This  ﬁnding
uggests that  the  entity  EBV+  DLBCL  of  the  elderly  can
ccur in  pediatric  and  young  immunocompetent  patients
nd might  not  be  an  age  related-EBV  association.  In  addi-
ion, latency  III  pattern  together  with  lytic  viral  antigen
xpression in  DLBCL  from  Argentina  suggest  that  lytic  cycle
ay play  an  unexpected  role  in  virus-mediated  oncogene-
is.
In order  to  reinforce  the  hypothesis  of  EBV-association
ot exclusively  related  to  elderly  patients,  DLBCL  microen-
ironment was  studied  in  pediatric,  younger  and  older  than
0 years  old  patients.  CD3,  CD8,  CD4  and  Foxp3  positive
ells were  compared  in  those  three  groups  and  in  rela-
ion to  EBV  presence.  Remarkably,  we  did  not  observe
ajor differences  linked  with  age  of  the  relative  numbers
f any  T-cell  population  analyzed.40,42 This  fact,  together
ith EBV  association  with  both  age  groups,  might  con-
rm previous  statements  that  the  deﬁnitional  cutoff  of  50
ears proposed  by  the  WHO  could  be  arbitrary48 because
ases <  50  years  of  age  can  be  found  and  suggest  that,  at
east for  T-cell  populations  analyzed,  immunosenescence
ould be  ruled  out.  Concerning  EBV  status,  no  signiﬁ-
ant difference  was  found  among  each  cellular  marker
nvestigated.40,42P.  Chabay,  M.V.  Preciado
. Concluding remarks and future
erspectives
rom  the  ﬁrst  discovery  of  EBV  particles  in  sub-Saharan
L, the  virus  has  now  been  found  in  many  more  tumors  of
, T,  NK  and  epithelial  cell  origin.  Overall,  EBV  seems  to
ontribute to  ∼2%  of  all  tumor  burdens  in  man.  Therefore,
he question  that  drives  most  research  into  EBV  since  its
iscovery is  why  some  individuals  develop  EBV-associated
umors, whereas  most  control  the  virus  without  symptoms.49
n  fact,  it  remains  to  be  elucidated  whether  EBV-association
ith lymphoma  reﬂects  causality.  The  increased  risk  of
L development  a  few  years  after  IM  leads  to  speculate
hat a  similar  association  may  exist  between  primary  EBV
nfection and  HL  risk  at  any  age,  for  example,  in  childhood.
 higher  prevalence  of  EBV  in  lymphomas  diagnosed  in
hildren <  10  years  old  was  demonstrated  by  our  research
roup not  only  in  pediatric  HL,20,21 but  also  in  BL34 and
LBCL.42 Therefore,  in  our  country,  EBV  infection  shows
nteresting epidemiological  characteristics  to  study  viral
athogenesis. Given  that  in  Argentina  children  are  infected
uite early  in  their  life  and  nearly  70%  of  children  are
eropositive by  the  age  of  2  years,10 we  hypothesize
hat infection  with  EBV  early  in  life  increases  the  risk
f developing  EBV-associated  lymphoma  and  may  be  as
 late  complication  of  primary  infection.  A  comparison
f EBV-positive  pediatric  lymphomas  between  developed
ountries and  our  own  data  from  Argentina  is  presented  in
able 1.  It  is  well  accepted  that  IM  often  precedes  HL  and
hat IM  is  an  adolescent/young  adult  disease,  but  to  our
nowledge there  is  not  a  clear  consensus  of  the  median  age
f  presentation  in  developed  countries.  Still  more  confusing
s the  literature  about  BL  and  DLBCL  because  most  studies
o not  distinguish  between  EBV-positive  and  -negative
ases and  because  of  the  multiple  presentation  forms;  for
nstance, BL  sporadic,  endemic  or  HIV  associated  and  DLBCL
f immunocompetent  or  immunosuppressed  patients.
Our  preliminary  results  in  tonsils  from  pediatric  carri-
rs show  that  a  latency  III  pattern  prevails  and,  based  on
he known  oncogenic  potential  of  EBV  in  vitro,  we  can  pro-
ose that  the  synergism  of  oncogenic  viral  proteins  could
ccur in  these  cases  (personal  observations).  This  ﬁnding
uggests that  there  could  be  an  implication  of  EBV  infection
nvolved in  B-cell  lymphoma  development  in  our  country,
nd emphasizes  the  need  for  epidemiological  studies  involv-
ng different  centers  from  the  Latin  American  region  to
onﬁrm this  hypothesis.
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